Effects of Nasal-spraying LiveSpo Navax in Treatment of Influenza Virus in Children

NACompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

December 21, 2020

Primary Completion Date

March 31, 2022

Study Completion Date

April 22, 2022

Conditions
Acute Respiratory Tract Infections
Interventions
COMBINATION_PRODUCT

LiveSpo Navax

In Vietnam, LiveSpo Navax is manufactured as a Class-A medical device product (Product declaration No.210001337/PCBA-HN) under manufacturing standards approved by Hanoi Health Department, Ministry of Health, Vietnam (Certificate No YT117-19) and ISO 13485:2016.

DRUG

0.9% NaCl physiological saline

Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.

Trial Locations (1)

100000

International Center, Vietnam National Children's Hospital, Hanoi

All Listed Sponsors
lead

National Children's Hospital, Vietnam

OTHER

NCT05378022 - Effects of Nasal-spraying LiveSpo Navax in Treatment of Influenza Virus in Children | Biotech Hunter | Biotech Hunter